Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma by Mir, Shahryar E. et al.
Trimethylation of H3K27 during
human cerebellar development
in relation to medulloblastoma
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Mir, Shahryar E., Michiel Smits, Dennis Biesmans, Machteld
Julsing, Marianna Bugiani, Eleonora Aronica, Gertjan J.L. Kaspers,
Jacqueline Cloos, Thomas Würdinger, and Esther Hulleman. 2017.
“Trimethylation of H3K27 during human cerebellar development





Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions




Trimethylation of H3K27 during human cerebellar development 
in relation to medulloblastoma
Shahryar E. Mir1,2, Michiel Smits2, Dennis Biesmans1,2, Machteld Julsing2, Marianna 
Bugiani3, Eleonora Aronica4, Gertjan J.L. Kaspers1,2, Jacqueline Cloos1,2,5, Thomas 
Würdinger2,6 and Esther Hulleman1,2
1Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
2Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, VU University Medical 
Center, Amsterdam, The Netherlands
3Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
4Department of (Neuro) Pathology, Academic Medical Center and Swammerdam Institute for Life Sciences, Center for 
Neuroscience, University of Amsterdam, Amsterdam, The Netherlands
5Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
6Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Correspondence to: Esther Hulleman, email: e.hulleman@vumc.nl
Keywords: medulloblastoma, cerebellum, brain development, histone 3 trimethylation, immunohistochemistry
Received: June 21, 2015    Accepted: August 17, 2017    Published: September 08, 2017
Copyright: Mir et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
Medulloblastoma (MB), the most common malignant childhood brain tumor, 
encompasses a collection of four clinically and molecularly distinct tumor subgroups, 
i.e. WNT, SHH, Group 3 and Group 4. These tumors are believed to originate from 
precursor cells during cerebellar development. Although the exact etiology of these 
brain tumors is not yet known, histone modifications are increasingly recognized as 
key events during cerebellum development and MB tumorigenesis. Recent studies 
show that key components involved in post-translational modifications of histone 
H3 lysine 27 (H3K27) are commonly deregulated in MB. In this descriptive study, 
we have investigated the trimethylation status of H3K27, as well as the expression 
of the H3K27 methylase EZH2 and demethylases KDM6A and KDM6B, during human 
cerebellum development in relation to MB. H3K27 Trimethylation status differed 
between the MB subgroups. Moreover, trimethylation of H3K27 and expression of its 
modifiers EZH2, KDM6A and KDM6B were detected in a spatio-temporal manner during 
development of the human cerebellum, with consistent high occurrence in the four 
proliferative zones, which are believed to harbor the precursor cells of the different 
MB subgroups. Our results suggest that H3K27 trimethylation in MB is deregulated by 
EZH2, KDM6A and KDM6B. Moreover, we provide evidence that during development 
of the human cerebellum H3K27me3 and its regulators are expressed in a spatio-
temporal manner.
INTRODUCTION
During development, cerebellar neurons are 
generated from two anatomically and molecularly distinct 
progenitor zones: the cerebellar ventricular zone (VZ) 
and the rhombic lip (RL) [1–3]. The VZ gives rise to 
all the GABAergic neurons, including Purkinje cells 
and inhibitory interneurons. The RL gives rise to all 
glutamatergic neurons, including granule neuron precursor 
cells (GNPs), unipolar brush cells and deep nuclei 
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neurons. Exiting the RL, GNPs migrate rostrally across 
the pial surface of the cerebellum and form a secondary 
germinal zone, the external germinal layer (EGL). This 
cell layer proliferates extensively until the first months 
postnatal, producing granule cells which reside in the 
internal granule layer (IGL). These proliferative zones 
are present during cerebellar development at a specific 
spatio-temporal manner [2, 3]. Medulloblastomas (MB) 
are highly invasive primitive neuroectodermal tumors, 
which are believed to originate from aberrantly dividing 
precursor cells present during cerebellar development 
[4]. MB are considered to encompass a collection of four 
clinically and molecularly distinct tumor subgroups [5–
7]. For two of these subgroups the cell of origin has been 
identified. The first subgroup has aberrant activation of 
the Sonic Hedgehog (SHH) pathway and originates from 
GNPs of the developing cerebellum [8, 9]. The second 
subgroup has activating mutations in the WNT pathway 
effector beta-catenin 1 (CTNNB1) and arises outside the 
cerebellum from cells of the lower RL located at the dorsal 
brainstem during early hindbrain development [10]. For 
the other MB subgroups, i.e. Group 3 and Group 4, the 
pathological processes that drive tumor formation remain 
elusive, although these tumors show GABAergic (Group 
3) and glutamatergic features (Group 4) [11–13].
Epigenetic gene regulation is essential for neural 
differentiation and crucial during human cerebellum 
development [14–16]. Histone modifications, such as 
histone acetylation, are associated with active gene 
transcription, whereas others such as the trimethylation 
of histone H3 lysine 27 (H3K27me3) are an indicator 
of condensed and inactive chromatin [17]. Important 
regulators of histone modification are the polycomb 
group protein complexes. The Enhancer of zeste homolog 
2 (EZH2) is an essential member of these complexes, 
as it has methyltransferase activity. EZH2 specifically 
trimethylates H3K27, leading to target gene silencing 
[18]. Counterparts of these repressive complexes are the 
histone demethylases KDM6A and KDM6B, which can 
specifically remove methyl marks of H3K27, and are able 
to activate silenced genes [19–21].
Deregulation of H3K27 trimethylation has 
recently been identified in all subgroups of MB [22–25]. 
Genome-wide mutation analyses in MBs have identified 
inactivating mutations in KDM6A and KDM6B, the two 
demethylases of H3K27, in respectively 8% and 0.3% 
of sequenced MB [22, 23]. Moreover, KDM6A (Xp11.3) 
and KDM6B (17p13.1) are also affected at a copy number 
level as deletions have been identified in almost 30% 
of MB cases [23]. Overexpression of EZH2 has been 
reported in several types of cancers, [26–29], including 
MB where EZH2 (7q36.1) is gained and overexpressed 
in almost 14% of MB cases [23]. Moreover, functional 
studies have provided compelling evidence that targeting 
EZH2 in MB activates silenced tumor suppressor genes 
and reduces stem cell properties in MB cell lines and 
transforming capacity in neural stem cells [30, 31]. 
Although deregulation of H3K27me3 occurs in all MB 
subgroups, the strongest effects are observed in Group 3 
and Group 4 MB [23–25]. Importantly, in these subgroups 
increased trimethylation of H3K27 leads to poor outcome 
[23]. While H3K27 methylation status seems to play 
an important role in MB, its role during cerebellum 
development has not been evaluated previously. Since MB 
are believed to arise from aberrantly dividing precursor 
cells present during cerebellar development, in this 
Figure 1: Expression of H3K27 and its modifiers in medulloblastoma. Representative selection of immunohistochemical 
staining for KDM6A, KDM6B, EZH2 and H3K27me3 in MB samples of different subgroups.
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descriptive study we have investigated the expression of 
EZH2, KDM6A, KDM6B and the H3K27me3 at various 
developmental stages of the human cerebellum.
RESULTS
H3K27me3 and its regulators are expressed 
differentially in MB subgroups
We evaluated the presence of the chromatin 
H3K27me3 mark and the expression of the methylase 
EZH2 and demethylases KDM6A and KDM6B in a 
selection of MB samples with known subgroup status. 
A subgroup specific expression pattern was observed, 
with increased trimethylation for H3K27 and increased 
EZH2 expression in group 3 and group 4 MB samples 
(Figure 1). The increased H3K27me3 in these subgroups 
also correlated with low protein expression of KDM6B. 
The expression of KDM6A was relatively high in 
most samples and did not correlate with any subgroup. 
Intermediate expression for EZH2 and H3K27me3 was 
found for SHH medulloblastoma samples, with both low 
and high expression of KDM6A and KDM6B. The WNT 
group samples had the lowest expression of EZH2 and 
H3K27me3, combined with relatively higher KDM6A 
and KDM6B protein levels (Figure 1). These results are in 
line with previous studies showing aberrant trimethylation 
of H3K27 in a subgroup-specific manner in MB [23, 24].
The expression of H3K27me3 and its regulators 
in developing human cerebellum
MB is considered to arise through transformation 
of early developmental progenitor cells [4]. To identify 
potential precursors for H3K27 deregulated MB, we 
evaluated the presence of H3K27 markers during human 
cerebellum development.
First, we analyzed transcriptional data previously 
published as part of the BrainSpan Atlas of the Developing 
Human Brain (http://brainspan.org/) [32]. The gene 
expression data for EZH2, KDM6A and KDM6B were 
analyzed for the periods spanning from embryonic 
(9 weeks GSA) until birth/early infancy (40 weeks). 
Throughout the prenatal period EZH2 displayed high 
mRNA expression in the developing human brain. This 
expression then dropped significantly after birth, with 
consistent low expression onwards (Figure 2A). KDM6A 
was also highly expressed prenatally, although expression 
varied between different brain regions and samples 
(Figure 2B). KDM6B expression was less consistent 
during prenatal development, with a trend towards lower 
expression during postnatal periods (Figure 2C).
To further evaluate the trimethylation status of 
H3K27 in human cerebellum development, we established 
a cohort of human cerebellum samples during different 
time points of development, ranging from gestational age 
(GSA) 9 weeks till 40 weeks. At least two samples per 
gestational age were investigated, with no difference in 
expression between samples.
At 9 weeks of gestation all important proliferative 
zones could be visualized (the VZ, upper- and lower RL 
and the EGL). Staining with an antibody directed against 
EZH2 showed a strong nuclear signal in all these different 
zones (Figure 3a–3f). However, at later time points 
EZH2 expression was markedly reduced and restricted. 
Between 28 weeks and 33 weeks gestation EZH2 was only 
detectable in part of the EGL (Figure 3g and 3h). After 
34 weeks GSA EZH2 could not be detected in any layer 
of the human cerebellum (data not shown and Figure 3i).
During early cerebellar development (9 weeks GSA) 
an uniformly high protein expression for KDM6A was 
detected in all the proliferative zones (Figure 4a–4f and 
Supplementary Figure 1). At 28 weeks gestation, strong 
nuclear KDM6A expression was observed in Purkinje 
cells, and to a lesser extent in the granule neuron precursor 
cells In the EGL and in the granule cells in the IGL (Figure 
4g). After 28 weeks GSA KDM6A could not be detected 
in any layer of the human cerebellum (Figure 4h–4i). 
KDM6B expression showed a bi-temporal expression 
pattern. During early cerebellar development (9 weeks 
GSA), KDM6B was present in the VZ, both upper and 
lower RL and EGL (Figure 5a–5f). However, compared to 
EZH2 and KDM6A fewer cells stained positive. Especially 
fewer KDM6B positive cells were present in both upper 
and lower RL. In contrast, KDM6B expression was more 
prominent in the VZ as compared to EZH2 (Figure 3e 
and 5e). Interestingly, the expression and localization 
of KDM6B changed during development. At 28 weeks 
gestation, expression of KDM6B was predominantly 
observed in Purkinje cells, and to a lesser extent in 
granule cells in the internal granule layer. Moreover, the 
staining intensity in Purkinje cells became more prominent 
in later stages and in adulthood (Figure 5g–5i and data 
not shown). The distribution of the signal also changed 
from only nuclear at 9 weeks GSA to predominantly 
cytoplasmic staining in Purkinje cells after 28 weeks GSA 
(Figure 5g–5i).
H3K27me3 showed a staining pattern that was 
comparable to EZH2 during early development (Figure 
6a–6f). All proliferative zones showed strong H3K27me3 
positive progenitor cells. During later development 
H3K27me3 staining was more localized in Purkinje 
cells, while a few positive cells could also be detected in 
the EGL and the internal granular layer (Figure 6g–6i). 
Whereas KDM6B staining in the Purkinje cells became 
more intense during development, H3K27me3 positive 
Purkinje cells became less intense (Figure 6g–6i). In 
contrary to the cytoplasmic localization of KDM6B in 
Purkinje cells, H3K27me3 staining was restricted to the 
cell nucleus (Figure 5i and 6i).
In conclusion, during development of the human 
cerebellum H3K27me3 and its regulators are expressed in 
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Figure 2: Dot plot showing transcript levels of EZH2 (A), KDM6A (B) and KDM6B (C) during human development as reported in the 
Brainspan database. Depicted are stage 2A (corresponding with 9 weeks GSA; early prenatal – blue), stage 5 (corresponding to 28 and 33 
weeks GSA; late prenatal – gray), and stage 6 (corresponding to 40 weeks GSA; birth-early infancy – yellow).
Figure 3: EZH2 expression during human cerebellum development. (a) Expression of EZH2 at 9 weeks GSA. (b-f) Higher 
magnifications (400x) of boxed areas showing high EZH2 expression in the proliferative zones of the developing cerebellum; upper RL 
(c), EGL (d), VZ (e), and lower RL (f). Expression of EZH2 is only detectable in the EGL layer between 28 weeks gestation (g) and 33 
weeks gestation (h). Higher magnification of boxed area in (h) shows the EZH2 positive cells in the EGL layer. After 33 weeks no EZH2 
expression can be detected in the cerebellum (i). Scale bars 1000 μm (b), 25 μm (c-i), 5 μm (inset in h).
Oncotarget78982www.impactjournals.com/oncotarget
a spatio-temporal manner. A summary of the expression 
patterns of EZH2, KDM6A and KDM6B and the 
trimethylation of H3K27 is given in Table 1.
DISCUSSION
Since the onset of MB is thought to be associated 
with a block in normal differentiation, and histone 
methylation patterns are frequently altered in MB, we 
investigated the pattern of H3K27me3 and its methylase 
EZH2 and demethylases KDM6A and KDM6B during 
human cerebellum development. Here, we provide 
evidence that during development of the human 
cerebellum H3K27me3 and its regulators are expressed in 
a spatio-temporal manner. Moreover, in line with previous 
studies, an aberrant expression pattern was seen in specific 
MB subgroups.
In recent years, four distinctive subgroups have 
been identified in MB: SHH, WNT, group 3, and group 
4. Although an H3K27me3 enriched phenotype has 
been described exclusively for Group 3 and Group 4 
MBs, amplification of EZH2 (gain of chromosome 7q) 
and deletion of KDM6B (loss of chromosome 17p) are 
also found in SHH MBs [23]. Moreover, both EZH2 
and KDM6B have been linked to SHH signaling during 
cerebellar development [33]. The SHH subgroup is 
thought to arise from the EGL [8]. Here we observed 
temporal expression of H3K27me3, EZH2, KDM6A 
and KDM6B at 9 weeks gestation in the EGL. KDM6B 
became undetectable after 9 weeks GSA. Expression of 
EZH2, KDM6A, and H3K27me3 however decreased 
rapidly in the EGL layer, with only a few positive cells 
between 28 and 33 weeks gestation. Li et al., have 
identified a subpopulation of Nestin positive progenitor 
cells (NEPs) within the EGL layer, which were found 
to be distinct from GNPs. When SHH signaling was 
aberrantly activated, these NEPs exhibited more severe 
genomic instability and gave rise to tumors more 
efficiently than GNPs [34]. EZH2 positive cells like 
the NEPs were present transiently during cerebellum 
Figure 4: KDM6A expression during human cerebellum development. (a) Expression of KDM6A expression at 9 weeks 
gestation. (b-f) Higher magnifications (400x) of boxed areas showing high KDM6A expression in the proliferative zones of the developing 
cerebellum; upper RL (c), EGL (d), VZ (e), and lower RL (f). At 28 weeks gestation, strong nuclear KDM6A expression was observed in 
Purkinje cells, and to a lesser extent in the granule neuron precursor cells In the EGL and in the granule cells in the IGL (g). After 28 weeks 
GSA KDM6A could not be detected in any layer of the human cerebellum (h-i). Scale bars 1000 μm (b), 100 μm (g), 50 μm (h), 25 μm 
(c-f and i).
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development in the EGL (Figures 3f and g). It is tempting 
to speculate whether the EZH2 positive cells within the 
EGL cells between 28 and 33 weeks gestation could be in 
fact these NEPs.
For the WNT subgroup, progenitor cells of the 
lower RL have been identified as cells of origin, which 
normally give rise to the pontine grey matter [10]. During 
early human cerebellum development EZH2, KDM6A and 
KDM6B were highly expressed in the lower RL at 9 weeks 
gestation and high levels of H3K27me3 were detected. 
Several studies have addressed the important role of 
EZH2 and KDM6B in brainstem development [35, 36]. In 
mouse pre-cerebellar neurons, EZH2 expression controls 
proper pontine neuron migration [35]. Moreover, KDM6B 
controls appropriate organization of the Pre-Bötzinger 
complex, a cluster of interneurons in the brainstem which 
control the respiratory rhythm generator [36]. Results 
from both studies, showing high expression patterns for 
EZH2, KDM6B and H3K27me3 in progenitors of lower 
RL during mouse brain development, are in line with our 
results in the human cerebellum.
Group 3 and Group 4 MB more commonly show 
deregulation of H3K27 trimethylation as compared to 
the SHH or WNT MBs. These subgroups predominantly 
show somatic copy number aberrations and mutations 
of EZH2,KDM6A and KDM6B [23–25]. Seen from a 
developmental point of view, the GABAergic (Group 3) 
and glutamatergic (Group 4) gene profiles point toward 
possible different precursor cells of origin for these MBs. 
During development GABAergic neurons are derived from 
precursors of the VZ expressing Pancreatic transcription 
factor 1a (PTF1A) [1]. We have shown that H3K27me3, 
EZH2, KDM6A and KDM6B are temporally present in 
the VZ at 9 weeks gestation. Later during development, 
trimethylation of H3K27 and expression of KDM6A and 
KDM6B could be detected in the GABAergic derived 
Purkinje cells starting from 28 weeks GSA. Moreover, 
KDM6B expression became stronger during further 
development in the Purkinje cells. KDM6B expression in 
Purkinje cells shifted from nuclear to cytoplasmic, which 
might suggest that in Purkinje cells KDM6B is involved in 
demethylating non-histone proteins as previously shown 
Figure 5: KDM6B expression during human cerebellum development. (a) Expression of KDM6B at 9 weeks gestation. (b-f) 
Higher magnifications (400x) of boxed areas showing high KDM6B expression in the proliferative zones of the developing cerebellum; 
upper RL (c), EGL (d), VZ (e), and lower RL (f). During further development KDM6B is selectively expressed in the Purkinje cells. 
Staining intensity increases in time, and distribution changes from nuclear to more cytoplasmic (f-i). Scale bars 1000 μm (b), 100 μm (g), 
50 μm (h), 25 μm (c-f and i).
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Figure 6: H3K27me3 trimethylation during human cerebellum development. (a) Expression of H3K27me3 at 9 weeks 
gestation. (b-f) Higher magnifications (400x) of boxed areas showing high H3K27me3 expression in the proliferative zones of the 
developing cerebellum; upper RL (c), EGL (d), VZ (e), and lower RL (f). At 28 weeks gestation strong staining is present in Purkinje cells 
and some cells in the EGL and IGL layers (g). From 33 weeks gestation and further H3K27me3 expression is only present in Purkinje cells 
(h-i). Scale bars 1000 μm (B), 25 μm (c-i).
Table 1: Summary of H3K27 regulators expression in the developing human cerebellum
Week 9 GSA Week 28 GSA Week 33 GSA Week 40 GSA
URL EGL VZ LRL EGL ML PCL IGL EGL ML PCL IGL EGL ML PCL IGL
EZH2 +++ +++ +++ +++ + - - +/- + - - - - - - -
KDM6A +++ ++ +++ +++ + - ++ +/- - - - - - - - -
KDM6B ++ ++ +++ ++ - - ++ +/- - - +++ +/- - - +++ +/-
H3K27me3 +++ +++ +++ +++ + +/- + + + +/- ++ + +/- - +/- +
URL, upper rhombic lip; EGL, external granule layer; VZ, ventricular zone; LRL, lower rhombic lip; ML, molecular layer; 
PCL, Purkinje cell layer; IGL, internal granule layer. Relative staining intensity is indicated as: - absent staining; + / - weak 
and sporadic staining; + low intensity staining or strong sporadic staining; ++ medium intensity staining; +++ high intensity 
staining.
for primary human fibroblasts [37]. Interestingly, the 
increase in KDM6B expression in Purkinje cells coincided 
with an increase in H3K27me3 in week 33, despite the 
absence of EZH2. Since it has been described previously 
that EZH2 deficient mouse models still show H3K27me2 
and H3K27me3 marks [38, 39], this suggests that H3K27 
methylation may occur through other methyltransferases, 
such as EZH1. According to the BrainSpan Atlas of the 
Developing Human Brain cerebellar transcript levels 
of EZH1 increase indeed at 25-38 weeks GSA (http://
brainspan.org/).
Elevated levels of H3K27me3 in human cerebellum 
have been described in Ataxia-telangiectasia, a 
neurodegenerative disease. In the same study, H3K27me3 
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staining was shown to be low in Purkinje cells of healthy 
adults, in line with our results [40]. During development 
all glutamatergic neurons are derived from precursor cells 
of the upper RL [41, 42]. We detected strong expression of 
EZH2, KDM6A, KDM6B and H3K27me3 in the upper RL 
at 9 weeks gestation. Whether precursors of GABAergic 
and glutamatergic neurons drive Group 3 and Group 4 
MB has recently received greater interest [13, 43]. The 
consistent high expression of EZH2 across different MB 
subgroups [30, 31, 44], and no expression of EZH2 after 
week 34 GSA, provides a possibility for targeted therapy 
with EZH2 inhibitors in medulloblastoma [31, 45, 46]. 
However, more preclinical experiments may be needed 
before implementing such inhibitors into clinical practice, 
as recent evidence suggests that deletion of EZH2 in group 
3 tumors may also accelerate tumorigenesis [47].
In conclusion, our data show the spatio-temporal 
expression of H3K27me3 and its modifiers during human 
cerebellar development, and the comparison with the 
subtypes of MB indicate that the H3K27 methylation 
pathway is deregulated in MB.
MATERIALS AND METHODS
Fetal brain and MB tissue array samples
A database containing fetal autopsy cases that 
underwent a comprehensive neuropathological evaluation 
during the last 30 years was available at our hospital. 
We selected samples of cases between the gestational 
ages of 9–40 weeks and reviewed all Hematoxylin and 
Eosin stained sections and paraffin embedded blocks. 
Specimens were excluded if there were significant 
neuropathological findings, or if they showed any 
evidence of autolysis. At least two samples per gestational 
age were investigated. In addition, a largely independent 
tissue microarray (TMA) cohort with medulloblastoma 
specimen (n=87) was obtained from the files of the 
Department of Neuropathology of the Academic Medical 
Center (University of Amsterdam). Subgroup information 
was obtained by immunohistochemistry using antibodies 
for the subgroup-specific protein markers β-catenin 
(WNT), DKK1 (WNT), SFRP1 (SHH), NPR3 (Group 
3), and KCNA1 (Group 4) as described by Northcott et 
al. [48]. Informed consent was obtained according to 
institutionally-approved protocols.
Immunohistochemistry
Immunohistochemical staining was performed on 
formalin-fixed, paraffin-embedded 4-μm sections of tissue 
of the various developmental stages. For all sections, 
heat induced antigen retrieval was carried out in a 
microwave in a 10 mM citrate buffer (pH 6). Endogenous 
peroxidase was blocked for half an hour in 0.3% H2O2 
in methanol. Afterwards, sections were stained for 
monoclonal mouse anti-EZH2 (1:200; cat. NCL-L-EZH2, 
Novacastra), polyclonal rabbit anti-KDM6A (1:750; cat. 
HPA001165, Sigma Aldrich), polyclonal mouse anti-
KDM6B, C-terminus (1:200; cat. AP1022b, Abgent), and 
monoclonal rabbit anti-H3K27me3 (1:200; cat. 9733, Cell 
Signaling), all diluted in standard antibody diluents. As 
a negative control, the staining protocol was followed 
without adding primary antibodies. As a positive control 
tonsil tissue was stained for EZH2 and H3K27me3, 
placental tissue for KDM6A and neocortex tissue for 
KDM6B. Primary antibodies EZH2 were incubated 
for 30 min. Primary antibodies KDM6A, KDM6B and 
H3K27me3 were incubated overnight. DAB was used as 
a substrate for the peroxidase based Envision detection 
system (cat.K4065, DAKO, Heverlee, Belgium). Slides 
were counterstained with Hematoxylin.
Datamining
Immunohistochemical stainings were compared to 
mRNA expression of EZH2, KDM6A, and KDM6B during 
human embryonal development described by Miller et al. 
[32], using the R2 genomics analysis and visualization 
platform (http://r2.amc.nl): normal brain development 
– brain span – 524 – rpkm – brspv10rs. Time points 
used are stage 2A (early prenatal, corresponding with 9 
weeks GSA), stage 5 (late prenatal, corresponding with 
28-33 weeks GSA), and stage 6 (birth-early infancy, 
corresponding with 40 weeks GSA).
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